drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous anti-CD19 CAR T-cell therapy that targets CD19 and kills malignant B cells via T-cell cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Brexucabtagene Autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti‑CD19 chimeric antigen receptor bind CD19 on malignant B cells, triggering CAR signaling (CD3ζ with costimulation), T‑cell activation/expansion, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of CD19‑positive cells.
drug_name
Brexucabtagene Autoleucel (KTE-X19)
nct_id_drug_ref
NCT06482684